))
Robert Barrow - The Psychedelic Transformation
Manage episode 352795049 series 2850013
Contenu fourni par LSE SU Entrepreneurs. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par LSE SU Entrepreneurs ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
The Bits & Bytes Series - Robert Barrow
Hosted by Sia Sha
Robert Barrow is the CEO of MindMed, a psychedelic biotech company founded in 2019. MindMed was the first psychedelic company that was listed on the Nasdaq and is currently in clinical trials - for example, for exploring the efficacy of LSD on generalised anxiety disorder. 🧠📚 The company has a market cap of roughly 700m and has received investment from individuals such as Kevin O’Leary. 🏋️♀️
Rethink your brain health:
Timestamps:
1:35 - What are psychedelics?
2:45 - Why are psychedelics controversial? Is the controversy based on valid concerns?
7:25 - Has depression, anxiety, and disconnection been on the rise in recent years? Why is therapy not enough?
17:12 - Rob talks about his journey through MindMed, from a consultant to CEO, and the potential he saw in the company.
31:39 - Rob discuss development of psychedelics and how they plan to take it to market.
32:05 - Are there any adverse effects of the usage of psychedelics? How does MindMed test for them?
45:19 - How do psychedelics work on anxiety disorder?
1:00:00 - Rob discusses the end goal and vision of MindMed, and who he would like as colleagues in the company.
01:01:47 - Why did MindMed go public?
1:10:07 - Rob discuss planning for distribution channels
80 episodes
Partager
